ES2637150T3 - Cristal de derivado de dispiropirrolidina - Google Patents

Cristal de derivado de dispiropirrolidina Download PDF

Info

Publication number
ES2637150T3
ES2637150T3 ES13835941.9T ES13835941T ES2637150T3 ES 2637150 T3 ES2637150 T3 ES 2637150T3 ES 13835941 T ES13835941 T ES 13835941T ES 2637150 T3 ES2637150 T3 ES 2637150T3
Authority
ES
Spain
Prior art keywords
weight
crystal
present
mdm2
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13835941.9T
Other languages
English (en)
Spanish (es)
Inventor
Shoko Yoshida
Yuuichi Sugimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ES2637150T3 publication Critical patent/ES2637150T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13835941.9T 2012-09-06 2013-09-05 Cristal de derivado de dispiropirrolidina Active ES2637150T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012195761 2012-09-06
JP2012195761 2012-09-06
PCT/JP2013/073865 WO2014038606A1 (ja) 2012-09-06 2013-09-05 ジスピロピロリジン誘導体の結晶

Publications (1)

Publication Number Publication Date
ES2637150T3 true ES2637150T3 (es) 2017-10-11

Family

ID=50237214

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13835941.9T Active ES2637150T3 (es) 2012-09-06 2013-09-05 Cristal de derivado de dispiropirrolidina

Country Status (12)

Country Link
US (8) US9359368B2 (OSRAM)
EP (1) EP2894156B1 (OSRAM)
JP (1) JP6016284B2 (OSRAM)
KR (1) KR102217410B1 (OSRAM)
CN (1) CN104812757B (OSRAM)
BR (1) BR112015004816B1 (OSRAM)
CA (1) CA2884238C (OSRAM)
ES (1) ES2637150T3 (OSRAM)
IN (1) IN2015MN00464A (OSRAM)
RU (1) RU2647840C2 (OSRAM)
TW (1) TWI586668B (OSRAM)
WO (1) WO2014038606A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102564925B1 (ko) 2015-01-20 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
CA2976752C (en) * 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108135884A (zh) * 2015-10-23 2018-06-08 第三共株式会社 用于治疗aml的药物组合物和治疗有此需要的对象中的aml的方法
TWI806822B (zh) * 2015-10-23 2023-07-01 日商第一三共股份有限公司 製備治療癌症之醫藥組成物之用途
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CA3042260C (en) 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
CN110741004B (zh) 2016-12-23 2023-10-17 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
AU2018211975B2 (en) 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
CN114667147B (zh) 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
CR20230162A (es) 2020-09-14 2023-06-02 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
EP4655073A2 (en) 2023-01-26 2025-12-03 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
RU2312101C2 (ru) 2001-12-18 2007-12-10 Ф.Хоффманн-Ля Рош Аг Цис-имидазолины в качестве ингибиторов mdm2
EP1458380B1 (en) 2001-12-18 2008-03-19 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
RU2006144811A (ru) 2004-05-18 2008-06-27 Ф.Хоффманн-Ля Рош Аг (Ch) Новые цис-имидазолины
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
EA014445B1 (ru) * 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
AR059265A1 (es) * 2006-02-07 2008-03-19 Astrazeneca Ab Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)
KR101052706B1 (ko) 2006-03-13 2011-08-01 에프. 호프만-라 로슈 아게 스피로인돌리논 유도체
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
CA2661354C (en) 2006-08-30 2012-12-18 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
ES2342854T3 (es) 2006-09-21 2010-07-15 F. Hoffmann-La Roche Ag Derivados de oxindol como agentes anticancerosos.
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
AU2008234954B9 (en) 2007-03-29 2012-02-02 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
AU2009294673B2 (en) 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EP2380892B1 (en) 2009-01-16 2014-04-02 Daiichi Sankyo Company, Limited Imidazothiazole derivative having proline ring structure
US20100190814A1 (en) 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
BR112012011317A2 (pt) 2009-11-12 2019-09-24 Univ Michigan Regents antagonistas espiro-oxindóis de mdm2
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
CN103153302A (zh) 2010-04-09 2013-06-12 密歇根大学董事会 针对用于治疗疾病的mdm2抑制剂的生物标记
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20130200039A1 (en) 2010-09-08 2013-08-08 Basf Se Aqueous polishing compositions containing n-substituted diazenium dioxides and/or n'-hydroxy-diazenium oxide salts
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
US20120071499A1 (en) * 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
WO2012076513A1 (en) 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
WO2012121361A1 (ja) * 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶

Also Published As

Publication number Publication date
US20180155355A1 (en) 2018-06-07
CN104812757A (zh) 2015-07-29
BR112015004816A2 (pt) 2017-07-04
HK1210172A1 (en) 2016-04-15
US20170081335A1 (en) 2017-03-23
RU2015112098A (ru) 2016-10-27
US20170081337A1 (en) 2017-03-23
CA2884238A1 (en) 2014-03-13
US9359368B2 (en) 2016-06-07
US9718830B2 (en) 2017-08-01
US20150210707A1 (en) 2015-07-30
WO2014038606A1 (ja) 2014-03-13
TWI586668B (zh) 2017-06-11
JP6016284B2 (ja) 2016-10-26
KR102217410B1 (ko) 2021-02-18
IN2015MN00464A (OSRAM) 2015-09-04
TW201410681A (zh) 2014-03-16
JPWO2014038606A1 (ja) 2016-08-12
US20170081336A1 (en) 2017-03-23
CN104812757B (zh) 2016-11-09
US9745315B2 (en) 2017-08-29
RU2647840C2 (ru) 2018-03-21
KR20150048140A (ko) 2015-05-06
US9718831B2 (en) 2017-08-01
US20160244458A1 (en) 2016-08-25
EP2894156A1 (en) 2015-07-15
US9884871B2 (en) 2018-02-06
BR112015004816B1 (pt) 2022-04-26
US20180155356A1 (en) 2018-06-07
US9540386B2 (en) 2017-01-10
US10030030B2 (en) 2018-07-24
US10023578B2 (en) 2018-07-17
US20170081334A1 (en) 2017-03-23
CA2884238C (en) 2017-10-03
EP2894156B1 (en) 2017-05-17
EP2894156A4 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
ES2637150T3 (es) Cristal de derivado de dispiropirrolidina
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
ES3034158T3 (en) Novel salt of terphenyl compound
ES3044433T3 (en) Compositions for use in a method of treating an estrogen receptor associated cancer
ES2402524T5 (es) Sal de malato de la N-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida y formas cristalinas de la misma para el tratamiento del cáncer
RU2728827C2 (ru) Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
CN116096372B (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
TW202311259A (zh) 化合物i的新形式及其應用
ES3027566T3 (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
JP6880023B2 (ja) 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
WO2021098859A1 (zh) 氮杂七元环类抑制剂及其制备方法和应用
JP2018531280A6 (ja) 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
WO2022223020A1 (zh) 靶向活化与失活态kras g12d的抑制剂
BR112021005171A2 (pt) derivados de quinuclidina-3-ona e seu uso em tratamento de câncer
TWI752026B (zh) 一類蛋白激酶抑制劑
JP2020536113A (ja) 上皮成長因子受容体阻害剤
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
WO2020103939A1 (zh) 三唑并环类化合物、其制备方法、中间体和应用
ES2784325T3 (es) Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas
CN111205244B (zh) 噻唑并环类化合物、其制备方法、中间体和应用
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
EP4512808A1 (en) Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
KR20250154490A (ko) 방향족 아미드 유도체, 이의 제조 방법, 및 그의 용도
EP4393908A1 (en) Bis-pyrazolyl-methane compounds affecting kras
JP2021521282A (ja) Ｃｄｋ４／６阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用